Century Therapeutics’ Long-Term Follow-Up Study: Key Insights for Investors

Century Therapeutics, Inc. ((IPSC)) announced an update on their ongoing clinical study.

Study Overview: Century Therapeutics, Inc. is conducting a long-term follow-up study titled A Long-Term Follow-up Study for Subjects Previously Treated With A Century Therapeutics Cellular Therapy Product. The study aims to gather safety and survival data from participants previously treated with Century’s cellular therapy products. It focuses on identifying late adverse events and assessing long-term risks associated with these treatments, which are crucial for understanding the safety profile of these innovative therapies.

Intervention/Treatment: The study involves participants who have previously received an induced pluripotent stem cell (iPSC)-derived cellular therapy product. As a non-interventional study, it does not involve any new treatments but focuses on monitoring the long-term effects of past treatments.

Study Design: This observational study follows a cohort model with a prospective time perspective. It is designed to observe participants over an extended period, up to 180 months, to collect comprehensive safety and survival data without any masking or allocation of new interventions.

Study Timeline: The study began on March 3, 2023, with the last update submitted on June 24, 2025. These dates are significant as they mark the study’s initiation and the most recent updates, providing a timeline for tracking progress and data collection.

Market Implications: The ongoing study could influence Century Therapeutics’ stock performance by providing valuable safety data that may impact investor confidence. Positive long-term safety results could enhance the company’s market position, especially in the competitive cellular therapy industry, where safety and efficacy are paramount.

The study is currently recruiting, with further details available on the ClinicalTrials portal.